ENOV logo

ENOV Enovis Corporation

New York Stock Exchange · Medical - Devices · Healthcare

$26.06
+0.40 (+1.56%)

Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionals—including orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainers—who treat patien…

Market Cap: $1.50Bwww.enovis.com

Price (90d)

$26.61
$20.04$23.83$27.63$31.42
Apr 30Aug 7

Signal Score (90d)

100
100
Aug 8Aug 8

Quote

Day Range
$25.78 – $26.44
52-Week Range
$19.14 – $34.28
Volume
$676.9K
Market Cap
$1.50B
50-Day Avg
$24.93
200-Day Avg
$25.24
Prev Close
$25.66
Open
$25.78

Valuation & Ratios

P/E Ratio
-1.28
EPS
$-20.86
P/B Ratio
1.02
P/S Ratio
0.67
Debt/Equity
0.93
Current Ratio
2.02
Dividend Yield
+0.0%
Gross Margin
+59.8%

Returns & Efficiency

Return on Equity
-79.5%
Return on Assets
-30.9%
FCF Yield
+1.3%
EV/EBITDA
-3.44

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$2.25B$-1.18B$-20.86
2024$2.11B$-825.49M$-14.93
2023$1.71B$-33.26M$-0.61
2022$1.56B$-13.29M$-0.28
2021$1.43B$71.66M$-2.02

Social Signal Score

50
5d
30d
50
1 mentions
-5.2%
60d
50
1 mentions
+23.3%
90d
50
1 mentions
+9.6%
news: 1

Earnings

Thu, Nov 5(in 3 months)

Consensus estimate $0.79 per share

7of 7 quarters beat consensus

Typical surprise +8.5% (median, so one quarter with a near-zero estimate can't distort it)

  • Thu, Aug 6$0.90 vs $0.85beat
  • Thu, May 7$0.89 vs $0.82beat
  • Thu, Feb 26$0.95 vs $0.81beat
  • Thu, Nov 6$0.75 vs $0.67beat
  • Thu, Aug 7$0.79 vs $0.74beat
  • Thu, May 8$0.81 vs $0.74beat

Estimates and results for ENOV via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

ENOVhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsmarketbeat.com·7d ago·Neutral

    Enovis Q2 Earnings Call Highlights Enovis NYSE: ENOV reported second-quarter 2026 sales of $583 million, up 3% on a reported basis and 5% organically, as growth in its Reconstruction business offset a slower but still expanding Performance & Recovery segment. Management said the company's results reflected improved commercial execution, new-product adoption and operational productivity, while also noting pressure from Middle East-related disruptions and higher inflation.

    View source ↗